Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 17/20 | 0.79 |
| ▸ | EGFR | P00533 | 14/20 | 0.79 |
| ▸ | LCK | P06239 | 1/20 | 0.79 |
| ▸ | AURKA | O14965 | 1/20 | 0.63 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.63 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.57 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2251397 | 0.91 | ERBB2 (0.79) | ERBB2EGFRLCKAURKARPS6KB1 | |
| SCHEMBL2250642 | 0.87 | ERBB2 (0.63) | ERBB2EGFRLCKAURKARPS6KB1 | |
| SCHEMBL2253000 | 0.87 | EGFR (0.73) | ERBB2EGFRLCKAURKARPS6KB1 | |
| SCHEMBL2253167 | 0.87 | EGFR (0.70) | ERBB2EGFRLCKAURKARPS6KB1 | |
| SCHEMBL2250726 | 0.86 | EGFR (0.70) | ERBB2EGFRLCKERBB4 | |
| SCHEMBL2254116 | 0.86 | ERBB2 (0.71) | ERBB2EGFRLCKAURKARPS6KB1 | |
| SCHEMBL2255375 | 0.85 | EGFR (0.70) | ERBB2EGFRLCKAURKARPS6KB1 | |
| SCHEMBL2322666 | 0.85 | ERBB2 (0.77) | ERBB2EGFRLCKAURKARPS6KB1 | |
| SCHEMBL28768471 | 0.85 | ERBB2 (0.77) | ERBB2EGFRLCKAURKARPS6KB1 | |
| SCHEMBL5190835 | 0.85 | ERBB2 (0.77) | ERBB2EGFRLCKAURKARPS6KB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1844022-B1 | QUINAZOLINE DERIVATIVES FOR INHIBITING CANCER CELL GROWTH AND METHOD FOR THE PREPARATION THEREOF | HANMI SCIENCE CO LTD (KR) | 2013-08-14 | — | — | EP | disclosed |
| CN-101094840-B | Quinazoline derivatives for inhibiting the growth of cancer cells and methods for preparing the same | HANMI PHARM IND CO LTD | 2012-10-31 | — | — | CN | disclosed |
| US-8003658-B2 | Quinazoline derivatives for inhibiting cancer cell growth and method for the preparation thereof | HANMI HOLDINGS CO., LTD. (KR) | 2011-08-23 | — | — | US | disclosed |
| US-20080009509-A1 | Quinazoline Derivatives For Inhibiting Cancer Cell Growth And Method For The Preparation Thereof | HANMI PHARM CO., LTD (KR) | 2008-01-10 | — | — | US | disclosed |
| CN-101094840-A | Quinazoline derivatives for inhibiting the growth of cancer cells and methods for preparing the same | HANMI PHARM IND CO LTD (KR) | 2007-12-26 | — | — | CN | disclosed |
| EP-1844022-A1 | QUINAZOLINE DERIVATIVES FOR INHIBITING CANCER CELL GROWTH AND METHOD FOR THE PREPARATION THEREOF | Hanmi Pharm. Co., Ltd. (KR) | 2007-10-17 | — | — | EP | disclosed |
| WO-2006071017-A1 | QUINAZOLINE DERIVATIVES FOR INHIBITING CANCER CELL GROWTH AND METHOD FOR THE PREPARATION THEREOF | HANMI PHARM. CO., LTD. (KR) | 2006-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009509-A1 | Quinazoline Derivatives For Inhibiting Cancer Cell Growth And Method For The Preparation Thereof | MKI67, NQO2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | ERBB2 1693/4885EGFR 1400/4885LCK 1194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.